HEOR and market access outputs in formats your stakeholders already use.
Markov or decision-tree CEA with PSA, tornado diagrams, ICER outputs, and country-specific threshold analysis.
Payer-level BIM with market uptake, patient share, cost offsets, and scenario toggles.
Browser-based model with sliders and real-time scenario exploration — shareable with payers and HTA bodies.
Comprehensive disease-area landscape generated in 48 hours: HTA history, guidelines, and published evidence across 7 markets.
Structured report ranking evidence gaps by strategic priority with recommendations for clinical study design.
Concise clinical evidence narrative for FDA, EMA, or HTA dossier submissions with source citations.
Live dashboard tracking HTA decisions, payer positions, and reimbursement status across NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM.
Structured dossier narrative — clinical summary, PICOTS, economic model narrative, and appendices aligned to each HTA body template.
Q&A document with anticipated payer objections and structured counterarguments on efficacy, durability, and pricing.
Multi-country reimbursement summary covering coverage, formulary placement, access restrictions, and price benchmarking.
1–2 page briefing synthesizing clinical evidence, budget impact, and access context for field teams ahead of payer meetings.
Localized model and narrative adapted to country-specific epidemiology, unit costs, comparators, and HTA methodology.
From a CEA in Excel to a country-adapted value dossier — we'll show you the fastest path with ValueGen.AI.
Request a Demo